Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) is a biomedical innovation company that entered the public markets via a SPAC structure, filing its S-1 registration statement with the SEC in July 2020. The company operates in the healthcare and medical device sector, concentrating on the development of next-generation cardiovascular therapeutic platforms. Its lead programs include the BackBeat Cardiac Neuromodulation Therapy system, designed to address hypertension in pacemaker-indicated patients, and the Virtue sirolimus-coated angioplasty balloon targeting peripheral artery disease. Following completion of the de-SPAC transaction, Orchestra BioMed Holdings began trading on Nasdaq under OBIO. For complete filing history, transaction details, and real-time corporate data on OBIO, create a free account at SpacDesk.